Cytokinetics Shares Owned by Institutions

CYTK -  USA Stock  

USD 47.25  0.22  0.46%

Cytokinetics fundamentals help investors to digest information that contributes to Cytokinetics' financial success or failures. It also enables traders to predict the movement of Cytokinetics Stock. The fundamental analysis module provides a way to measure Cytokinetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytokinetics stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh

Cytokinetics Shares Owned by Institutions Analysis

Cytokinetics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Shares Held by Institutions 
 = 
Funds and Banks 
Firms 
More About Shares Owned by Institutions | All Equity Analysis

Current Cytokinetics Shares Owned by Institutions

    
  114.14 %  
Most of Cytokinetics' fundamental indicators, such as Shares Owned by Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytokinetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cytokinetics Shares Owned by Institutions Driver Correlations

Understanding the fundamental principles of building solid financial models for Cytokinetics is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Shares Owned by Institutions. Since Cytokinetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytokinetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytokinetics' interrelated accounts and indicators.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Compare to competition

Based on the latest financial disclosure, 114% of Cytokinetics are shares owned by institutions. This is 155.69% higher than that of the Healthcare sector and 140.29% higher than that of the Biotechnology industry. The shares owned by institutions for all United States stocks is 191.1% lower than that of the firm.

Cytokinetics Shares Owned by Institutions Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytokinetics' direct or indirect competition against its Shares Owned by Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytokinetics could also be used in its relative valuation, which is a method of valuing Cytokinetics by comparing valuation metrics of similar companies.
Cytokinetics is currently under evaluation in shares owned by institutions category among related companies.

Cytokinetics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Cytokinetics from analyzing Cytokinetics' financial statements. These drivers represent accounts that assess Cytokinetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytokinetics' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(932.77 K)(817.61 K)(780.08 K)(689.9 K)(586.69 K)(633 K)
Revenue Per Employee97.58 K242.31 K172.23 K302.58 K191.9 K212.66 K
Average Assets306.78 M242.16 M218.51 M374.25 M702.56 M758.02 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(122.85 M)(101.25 M)(113.78 M)(109.5 M)(196.6 M)(201.77 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(122.85 M)(101.25 M)(113.78 M)(109.5 M)(196.6 M)(201.77 M)
Earnings before Tax(127.79 M)(106.29 M)(121.69 M)(127.29 M)(215.31 M)(220.98 M)
Average Equity131.82 M63.19 M(8.08 M)34.8 M144.3 M116.66 M
Enterprise Value353.14 M360.05 M639.82 M1.41 B3.99 B4.3 B
Free Cash Flow(104.64 M)(102.09 M)(93.53 M)(2.11 M)(191.39 M)(196.43 M)
Invested Capital168.94 M189.91 M363.43 M558.56 M926.72 M999.89 M
Invested Capital Average203.78 M194.17 M230.69 M388.78 M814.76 M879.08 M
Market Capitalization439.16 M345.77 M626.86 M1.47 B3.82 B4.13 B
Tangible Asset Value294.81 M211.18 M289.81 M533.8 M841.32 M907.74 M
Working Capital241.85 M185.48 M207.73 M443.02 M463.81 M500.43 M

Cytokinetics Fundamentals

About Cytokinetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cytokinetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Cytokinetics Investors Sentiment

The influence of Cytokinetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Cytokinetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Cytokinetics Implied Volatility

    
  74.3  
Cytokinetics' implied volatility exposes the market's sentiment of Cytokinetics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cytokinetics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cytokinetics stock will not fluctuate a lot when Cytokinetics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytokinetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytokinetics' short interest history, or implied volatility extrapolated from Cytokinetics options trading.

Current Sentiment - CYTK

Cytokinetics Investor Sentiment

Most of Macroaxis users are currently bullish on Cytokinetics. What is your opinion about investing in Cytokinetics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Cytokinetics Piotroski F Score and Cytokinetics Altman Z Score analysis. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.1 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.